LEO Pharma A/S first developed and launched this product in Denmark in 2001 as a topical treatment for psoriasis vulgaris. The product is now approved and marketed in 97 countries worldwide, including the US, and is widely used as the first-line treatment for psoriasis vulgaris. LEO Pharma K.K. filed for the marketing and manufacturing approval of this product with the Ministry of Health, Labour and Welfare (MHLW) in Japan in August 2013 as the first topical active vitamin D3/steroid combination drug (once daily application) for the treatment of psoriasis.
Under the agreement reached by the three companies, Kyowa Hakko Kirin will pay LEO Pharma A/S an upfront and subsequent milestone payments. Upon launch LEO Pharma K.K. is responsible for supplying the product, and Kyowa Hakko Kirin is responsible for distribution and Medical Representatives (MRs) promotion of the product. Both companies will jointly conduct marketing activities. During the term of the agreement, LEO Pharma K.K. will plan to start MRs promotion of the product together with Kyowa Hakko Kirin.
LEO Pharma K.K. is developing its business to be a preferred care partner in the field of dermatology and is expanding its pipeline of dermatology therapies, including this drug. This partnership agreement marks an important step for LEO Pharma K.K., as it is the first time the company will directly market an in-house product in Japan. LEO Pharma K.K. is collaborating with Kyowa Hakko Kirin to provide patients in Japan with new treatment options in psoriasis.
Kyowa Hakko Kirin has positioned immunology/allergy as a strategic category. The company aims to support patients suffering from psoriasis vulgaris by marketing this drug.
About LEO Pharma K.K.
LEO Pharma K.K. was established in June 2010 as the wholly owned Japanese subsidiary of LEO Pharma A/S in Denmark. The company aims to establish a solid position as a specialty pharmaceutical company in Japan with expertise in the field of dermatology.
For more information, visit www.leo-pharma.jp.
About Kyowa Hakko Kirin Co., Ltd
Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world.
For more information, visit www.kyowa-kirin.com.